STAT+: This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?

Faeth closed its Series A funding round last month, but it still faces the challenge of demonstrating it has a successful business model.

For all the advances oncology researchers have made in genomics and precision medicine, one of the most basic questions for cancer patients remains one of the least understood.

What should I eat?

Continue to STAT+ to read the full story…